A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects
A Three-part Single-center, Phase 1 Study to Assess the Tolerability, Safety, Pharmacokinetics (Including Food Interaction), and Pharmacodynamics of Ascending Single and Multiple Doses of AC-084 in Healthy Subjects and to Investigate the Pharmacokinetics of a Single Dose of AC-084 in Healthy CYP2C9 Poor Metabolizers
Sponsor: Idorsia Pharmaceuticals Ltd.
Terminated
The study has been terminated due to difficulties in recruiting subjects into Part C. No safety concerns contributed to the termination of the study
Other terminated trials from Idorsia Pharmaceuticals Ltd.
- Healthy · Phase PHASE1 · Apr 2021
- Pulmonary Arterial Hypertension · Phase PHASE2 · Sep 2011
- Pulmonary Arterial Hypertension · Phase PHASE2 · Sep 2011
- Aneurysmal Subarachnoid Hemorrhage · Phase PHASE3 · Jan 2011
- Heart Diseases · Phase PHASE3 · Mar 2008
More terminations from Idorsia Pharmaceuticals Ltd.
Other Healthy Subjects trials with similar outcome
Listed as NCT02905253, this PHASE1 trial focuses on Healthy Subjects and remains terminated or withdrawn. Sponsored by Idorsia Pharmaceuticals Ltd., it has been updated 10 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE1
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE1
▶ Show 5 earlier versions
-
Aug 2018 — Nov 2020 [monthly]
Terminated PHASE1
-
Jun 2018 — Aug 2018 [monthly]
Terminated PHASE1
-
May 2018 — Jun 2018 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Apr 2017 — May 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Apr 2017 [monthly]
Recruiting PHASE1
First recorded
Sep 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Idorsia Pharmaceuticals Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .